



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: www.shyuanye.com  
邮箱: shyysw@sina.com

产品名称: INT-767

产品别名: INT-767

**生物活性:**

<b>Description</b>	INT-767 is a dual farnesoid X receptor (FXR)/TGR5 agonist with mean EC50s of 30 and 630 nM, respectively[1][2].						
<b>In Vitro</b>	INT-767 does not show cytotoxic effects in HepG2 cells, does not inhibit cytochrome P450 enzymes, is highly stable to phase I and II enzymatic modifications, and does not inhibit the human ether-a-go-go-related gene potassium channel[2].						
<b>In Vivo</b>	INT-767 (10-20 mg/kg; i.p.; daily for 2 weeks) decreases plasma total cholesterol and triglyceride levels in db/m and db/db mice [2].						
	<b>Animal Model:</b>	Male 8-week old C57BKS/J db/db mice, control nondiabetic db/m mice[2]					
	<b>Dosage:</b>	10, 20 mg/kg					
	<b>Administration:</b>	Intraperitoneal injection; daily for 2 weeks					
<b>Solvent&amp;Solubility</b>	<b>Result:</b>	Decreased plasma total cholesterol and triglyceride levels.					
	<b>In Vitro:</b>  DMSO : ≥ 205.5 mg/mL (415.44 mM)  * "≥" means soluble, but saturation unknown.						
	<b>Preparing Stock Solutions</b>	<b>Solvent</b> Mass Concentration	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>		
		1 mM	2.0216 mL	10.1080 mL	20.2159 mL		
		5 mM	0.4043 mL	2.0216 mL	4.0432 mL		
<b>References</b>	10 mM	0.2022 mL					
	1. Baghdasaryan A, et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mousecholangiopathy model by promoting biliary HCO3- output. Hepatology. 2011 Oct;54(4):1303-1312.						
	2. Rizzo G, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor andTGR5 agonist. Mol Pharmacol. 2010 Oct;78(4):617-630.						